306 related articles for article (PubMed ID: 18927302)
41. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.
Morgia G; Falsaperla M; Malaponte G; Madonia M; Indelicato M; Travali S; Mazzarino MC
Urol Res; 2005 Feb; 33(1):44-50. PubMed ID: 15517230
[TBL] [Abstract][Full Text] [Related]
42. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Yoshida O
J Urol; 1999 Apr; 161(4):1359-63. PubMed ID: 10081908
[TBL] [Abstract][Full Text] [Related]
43. Urinary matrix metalloproteinases as a potential screening test for gynecologic malignancies.
Bazzett LB; Magnus M; Taylor DD; Gercel-Taylor C
Gynecol Oncol; 2003 Aug; 90(2):435-42. PubMed ID: 12893214
[TBL] [Abstract][Full Text] [Related]
44. Imbalance of metallaproteinase/tissue inhibitors of metalloproteinase system in renal transplant recipients with chronic allograft injury.
Mazanowska O; Kamińska D; Krajewska M; Zabińska M; Kopeć W; Boratyńska M; Chudoba P; Patrzalek D; Klinger M
Transplant Proc; 2011 Oct; 43(8):3000-3. PubMed ID: 21996210
[TBL] [Abstract][Full Text] [Related]
45. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer.
Ramón de Fata F; Ferruelo A; Andrés G; Gimbernat H; Sánchez-Chapado M; Angulo JC
Actas Urol Esp; 2013 Sep; 37(8):480-8. PubMed ID: 23916137
[TBL] [Abstract][Full Text] [Related]
46. [Serum and urinary concentration of selected metalloproteinases and their tissue inhibitors in children with vesicoureteral reflux].
Taranta-Janusz K; Zoch-Zwierz W; Wasilewska A; Tenderenda E; Korzeniecka-Kozerska A
Pol Merkur Lekarski; 2010 Aug; 29(170):88-92. PubMed ID: 20842819
[TBL] [Abstract][Full Text] [Related]
47. Urine Levels of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Children with Type 1 Diabetes Mellitus.
Yürük Yıldırım Z; Yılmaz A; Pehlivanoğlu C; Gedikbaşı A; Yıldız M; Dirican A; Bundak R; Darendeliler F; Emre S; Nayır A
J Clin Res Pediatr Endocrinol; 2019 May; 11(2):157-163. PubMed ID: 30396876
[TBL] [Abstract][Full Text] [Related]
48. Gelatinase isoforms in urine from bladder cancer patients.
Monier F; Surla A; Guillot M; Morel F
Clin Chim Acta; 2000 Sep; 299(1-2):11-23. PubMed ID: 10900289
[TBL] [Abstract][Full Text] [Related]
49. MMP, VEGF and TIMP as prognostic factors in recurring bladder cancer.
Wieczorek E; Jablonowski Z; Tomasik B; Konecki T; Jablonska E; Gromadzinska J; Fendler W; Sosnowski M; Wasowicz W; Reszka E
Clin Biochem; 2015 Dec; 48(18):1235-40. PubMed ID: 26197083
[TBL] [Abstract][Full Text] [Related]
50. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
51. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
[TBL] [Abstract][Full Text] [Related]
52. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer.
Papathoma AS; Petraki C; Grigorakis A; Papakonstantinou H; Karavana V; Stefanakis S; Sotsiou F; Pintzas A
Anticancer Res; 2000; 20(3B):2009-13. PubMed ID: 10928143
[TBL] [Abstract][Full Text] [Related]
53. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease.
Manfredi MA; Zurakowski D; Rufo PA; Walker TR; Fox VL; Moses MA
Inflamm Bowel Dis; 2008 Aug; 14(8):1091-6. PubMed ID: 18338781
[TBL] [Abstract][Full Text] [Related]
54. Matrix metalloproteinase-2 and -9 in the sera and in the urine of human oncocytoma and renal cell carcinoma.
Di Carlo A
Oncol Rep; 2012 Sep; 28(3):1051-6. PubMed ID: 22711190
[TBL] [Abstract][Full Text] [Related]
55. Correlation between prenatal urinary matrix metalloproteinase activity and the degree of kidney damage in a large animal model of congenital obstructive uropathy.
Nicksa GA; O'Neil E; Yu DC; Curatolo AS; McNeish BL; Barnewolt CE; Zurakowski D; Buchmiller TL; Moses MA; Rosen S; Fauza DO
J Pediatr Surg; 2010 Jun; 45(6):1120-5. PubMed ID: 20620306
[TBL] [Abstract][Full Text] [Related]
56. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade.
Bianco FJ; Gervasi DC; Tiguert R; Grignon DJ; Pontes JE; Crissman JD; Fridman R; Wood DP
Clin Cancer Res; 1998 Dec; 4(12):3011-6. PubMed ID: 9865914
[TBL] [Abstract][Full Text] [Related]
57. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
58. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer.
Vasala K; Pääkkö P; Turpeenniemi-Hujanen T
Urology; 2003 Nov; 62(5):952-7. PubMed ID: 14624933
[TBL] [Abstract][Full Text] [Related]
59. Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis.
Sanders JS; Huitema MG; Hanemaaijer R; van Goor H; Kallenberg CG; Stegeman CA
Am J Physiol Renal Physiol; 2007 Dec; 293(6):F1927-34. PubMed ID: 17898039
[TBL] [Abstract][Full Text] [Related]
60. [Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in the urine of children with pyelonephritis].
Tenderenda E; Zoch-Zwierz W; Wasilewska A; Porowski T; Taranta-Janusz K; Kołodziejczyk Z; Michaluk-Skutnik J
Pol Merkur Lekarski; 2009 Jul; 27(157):10-3. PubMed ID: 19650421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
